Stock Analiz

Clinuvel Pharmaceuticals Ltd CUVL

Miscellaneous · data as of November 13, 2026

$5.05Market cap $255M
Open the interactive analysis →

Clinuvel Pharmaceuticals Ltd (CUVL) is a company listed in the US with a market value of about $255M. In fiscal year 2026 it had revenue of $64M and net income of $23M, a net margin of 36.0%.

Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is future growth (1/5).

Key numbers: a P/E of 11.2, a price to free cash flow of 21.5, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 3% below the current price.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is listed in the US and classified in miscellaneous. It was profitable in 3 of the last 3 years in our data. It spends 19% of revenue on research and development.

Score: 2.4 / 5

Value2/5
Future growth1/5
Track record1/5
Financial health5/5
Shareholder returns3/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • 5-year average ROIC above 12%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)11.2
Forward P/E—
P/FCF21.5
P/S4.0
P/B1.4
EV/EBITDA3.0
PEG—
Dividend yield0.71%
FCF yield4.7%
Shareholder yield0.7%
Intrinsic value vs. price−3%

Growth and quality

Revenue growth (1 yr)5.2%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)38.1%
ROIC (5-yr avg.)12.3%
Profitable years (of last 10)3
Years paying a dividend3

Financials, last 3 years

Fiscal year202620252024
Revenue$64M$61M$58M
Net income$23M$23M$23M
Free cash flow$12M$27M$20M
EPS (diluted)$0.46$0.46$0.46
Net margin36.0%37.8%40.3%
ROIC10.4%11.8%14.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Clinuvel Pharmaceuticals’s P/E ratio?

About 11.2, based on the last twelve months of diluted earnings per share.

Is Clinuvel Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 3% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Clinuvel Pharmaceuticals pay a dividend?

Yes. The dividend yield is about 0.71%, and it has paid dividends for 3 years in our data.

Is Clinuvel Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Clinuvel Pharmaceuticals scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.